Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00377390 · ClinicalTrials.gov registry record
ICATA Asthma Mechanistic Study
A clinical trial of Asthma, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 224
- Enrollment target
- 4
- Study locations
NCT00377390 is a study of Asthma that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 224 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (86% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT00377390, a study of Asthma, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 224 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purposes of this study are to determine the effects of omalizumab on cells involved in the allergic response, to evaluate predictors of response to omalizumab, and to determine whether response to omalizumab therapy is influenced by the environment. A subset of inner-city children and adolescents currently enrolled in Inner-City Anti-IgE Therapy for Asthma (a clinical trial of omalizumab) will be enrolled in this study.
Conditions Studied
Interventions
- BIOLOGICAL Omalizumab
Study Locations (4)
Illinois
- Children's Memorial Hospital - Chicago
New York
- Mount Sinai School of Medicine - New York
Ohio
- Rainbow Babies and Children's Hospital - Cleveland
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00377390
The ClinicalTrials.gov registry entry for NCT00377390 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (86% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Omalizumab is the first listed.
NCT00377390 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Illinois, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT00377390 about?
NCT00377390 is a clinical study titled "ICATA Asthma Mechanistic Study". The purposes of this study are to determine the effects of omalizumab on cells involved in the allergic response, to evaluate predictors of response to omalizumab, and to determine whether response to omalizumab therapy is influenced by the environment. A subset of inner-city children and adolescent...
What is the current status of trial NCT00377390?
This trial is currently completed. The enrollment target is 224 participants. The study started on 2006-10. Estimated completion is 2009-12.
What conditions does trial NCT00377390 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00377390?
The interventions under investigation include: Omalizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00377390?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00377390 being conducted?
This trial has 4 study locations across Illinois, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Innate Immunity in Allergic Asthma
RECRUITING
-
Automated Inhaler Monitoring for Asthma Medication Usage
RECRUITING · NA
-
Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology
RECRUITING
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.